WMJ‐S‐001, a novel aliphatic hydroxamate derivative, exhibits anti‐inflammatory properties via MKP‐1 in LPS‐stimulated RAW264.7 macrophages
Authors:
- 27 February 2015
- journal article
- Published by Wiley in British Journal of Pharmacology
- Vol. 172 (7) , 1894-1908
Abstract
Background and Purpose: Hydroxamate derivatives have attracted considerable attention because of their broad pharmacological properties. Recent studies reported their potential use in the treatment of cardiovascular diseases, arthritis and infectious diseases. However, the mechanisms of the anti‐inflammatory effects of hydroxamate derivatives remain to be elucidated. In an effort to develop a novel pharmacological agent that could suppress abnormally activated macrophages, we investigated a novel aliphatic hydroxamate derivative, WMJ‐S‐001, and explored its anti‐inflammatory mechanisms.Experimental Approach: RAW264.7 macrophages were exposed to LPS in the absence or presence of WMJ‐S‐001. COX‐2 expression and signalling molecules activated by LPS were assessed.Key Results: LPS‐induced COX‐2 expression was suppressed by WMJ‐S‐001. WMJ‐S‐001 inhibited p38MAPK, NF‐κB subunit p65 and CCAAT/enhancer‐binding protein (C/EBP)β phosphorylation in cells exposed to LPS. Treatment of cells with a p38MAPK inhibitor (p38MAPK inhibitor III) markedly inhibited LPS‐induced p65 and C/EBPβ phosphorylation and COX‐2 expression. LPS‐increased p65 and C/EBPβ binding to the COX‐2 promoter region was suppressed in the presence of WMJ‐S‐001. In addition, WMJ‐S‐001 suppression of p38MAPK, p65 and C/EBPβ phosphorylation, and subsequent COX‐2 expression were restored in cells transfected with a dominant‐negative (DN) mutant of MAPK phosphatase‐1 (MKP‐1). WMJ‐S‐001 also caused an increase in MKP‐1 activity in RAW264.7 macrophages.Conclusions and Implications: WMJ‐S‐001 may activate MKP‐1, which then dephosphorylates p38MAPK, resulting in a decrease in p65 and C/EBPβ binding to the COX‐2 promoter region and COX‐2 down‐regulation in LPS‐stimulated RAW264.7 macrophages. The present study suggests that WMJ‐S‐001 may be a potential drug candidate for alleviating LPS‐associated inflammatory diseases.Keywords
Funding Information
- the Chi Mei Medical Center, Tainan, Taiwan (102CM-TMU-12)
- the Ministry of Science and Technology of Taiwan (NSC 102-2320-B-038-047)
This publication has 62 references indexed in Scilit:
- Coactivation of TLR4 and TLR2/6 coordinates an additive augmentation on IL-6 gene transcription via p38MAPK pathway in U937 mononuclear cellsMolecular Immunology, 2011
- Metformin inhibits HMGB1 release in LPS‐treated RAW 264.7 cells and increases survival rate of endotoxaemic miceBritish Journal of Pharmacology, 2010
- MAPK phosphatase-1 facilitates the loss of oxidative myofibers associated with obesity in miceJournal of Clinical Investigation, 2009
- Acetylation of mitogen-activated protein kinase phosphatase-1 inhibits Toll-like receptor signalingJournal of Experimental Medicine, 2008
- Differential regulation and properties of MAPKsOncogene, 2007
- Antiinflammatory effects of dexamethasone are partly dependent on induction of dual specificity phosphatase 1Journal of Experimental Medicine, 2006
- CLINICAL DEVELOPMENT OF HISTONE DEACETYLASE INHIBITORS AS ANTICANCER AGENTSAnnual Review of Pharmacology and Toxicology, 2005
- Sequential phosphorylation of CCAAT enhancer-binding protein β by MAPK and glycogen synthase kinase 3β is required for adipogenesisProceedings of the National Academy of Sciences, 2005
- p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseasesNature Reviews Drug Discovery, 2003
- The Pathophysiology and Treatment of SepsisNew England Journal of Medicine, 2003